Dr. Leonard Alan Kalman serves as the interim system chief executive for Baptist Health Cancer Care and interim executive medical director for Miami Cancer Institute. A nationally recognized leader in oncology and healthcare transformation, Dr. Kalman has played a central role in shaping the Institute’s mission, multidisciplinary care model, and clinical excellence since its inception. He proudly notes that he was Miami Cancer Institute’s first employee, helping guide its development from concept to a nationally ranked cancer center.

After completing his medical oncology fellowship at Memorial Sloan Kettering Cancer Center in New York City, Dr. Kalman came to Miami in 1982, where he helped grow a small community practice into Advanced Medical Specialties (AMS)—one of the nation’s largest oncology group practices. When Miami Cancer Institute was established, the AMS physicians and staff who practiced at Baptist Health facilities became the Institute’s founding oncology team in 2014.

In his current role, Dr. Kalman oversees medical staff development, clinical program growth, and strategic initiatives that advance quality, innovation, and patient-centered care. Under his leadership, Miami Cancer Institute has grown to more than 130 physicians, delivered over 200,000 physician visits, and performed more than 20,000 surgeries and procedures in 2024. The Institute is consistently recognized by U.S. News & World Report among the top 10 percent of cancer care programs nationwide.

Dr. Kalman’s leadership continues to shape the future of cancer care in South Florida—anchored in excellence, collaboration, and compassion for every patient.

Dr. Mehta is an internationally renowned radiation oncologist, one of the world’s experts in the treatment of brain tumors, and a pioneer in the fields of radiosurgery, intensity-modulated image-guided radiotherapy, MR-Linac based radiotherapy, and pencil-beam scanning proton therapy. He has previously served as the Chair and Professor of Human Oncology at the University of Wisconsin, Professor of Radiation Oncology at Northwestern University, and the University of Maryland, where served as Professor of Radiation Oncology and Director of the Proton Therapy Center.

Dr. Mehta provides overall leadership and direction to the entire Radiation Oncology Division, including our unique Proton Therapy Center; mentors junior mid-career colleagues; develops and directs a far ranging clinical trials program in radiation oncology, including clinical trials evaluating the increasing importance of proton therapy in an expanding number of cancers, and remains clinically active, caring for patients with brain tumors and lung cancer.

As Deputy Director, he has a significant role in the operational and clinical development of and integration of all radiation modalities within Miami Cancer Institute, and also in future strategic planning for the organization. Because of his vast experience, he remains a key liaison with national radiation and proton organizations, with our academic alliance partner Memorial Sloan Kettering, with Baptist International and Baptist Finance, and with potential partners in the radiation oncology industry.

An internationally renowned expert in the application of both autologous and allogeneic stem cell transplantation for the treatment of leukemia, myelodysplastic syndrome, multiple myeloma and other lymphoproliferative diseases, Guenther Koehne, M.D., Ph.D., serves as deputy director and chief of Stem Cell Transplantation, Hematologic Oncology and Benign Hematology at Miami Cancer Institute, part of Baptist Health South Florida. Prior to joining the Institute in 2017, he was a leading physician in adult bone marrow transplantation at Memorial Sloan Kettering Cancer Center in New York and an Associate Professor of Medicine at Weill Cornell Medical College. Dr. Koehne is recognized for his work in adoptive immunotherapeutic approaches with antigen-specific, donor-derived T lymphocytes to treat viral complications following allogeneic transplants and the development of novel treatments for high-risk multiple myeloma, minimal residual disease of leukemia and relapsed disease post-allogeneic stem cell transplantation. A physician-scientist, Dr. Koehne has led the development and growth of the Institute’s outpatient and inpatient blood and bone marrow transplant program and is involved in numerous groundbreaking clinical trials.

Dr. Koehne is Board certified in internal medicine and medical oncology. He received his medical degree and Ph.D. from Medical University of Hamburg, Germany, where he also trained as a resident in internal medicine. He completed an additional internal medicine residency at Rush University Medical Center in Chicago. His extensive training also includes a medical oncology/hematology fellowship at Memorial Sloan Kettering Cancer Center and a research fellowship in the Immunology Program at the Sloan Kettering Institute for Cancer Research, Allogeneic Bone Marrow Transplantation Service.

Dr. Koehne is a member of the American Society of Hematology, American Society for Blood and Marrow Transplantation and the American Society of Clinical Oncology. He champions the Leukemia & Lymphoma Society and has served as Chairman of the Light the Night Walk, the organization’s largest fundraiser.

Manmeet Ahluwalia, M.D., MBA, FASCO, is the chief scientific officer, chief of medical oncology, deputy director and Fernandez Family Endowed Chair in Cancer Research at Baptist Health Miami Cancer Institute.

As a neuro-oncologist, Dr. Ahluwalia’s primary areas of research and patient care are primary brain tumors (tumors originating in the brain that can be cancerous or noncancerous) and brain metastases (cancer that originated elsewhere in the body and has spread to the brain). Dr. Ahluwalia is fluent in English, Hindi and Punjabi.

In 2025, Dr. Manmeet S. Ahluwalia was elected to the American Society for Clinical Investigation (ASCI), one of the oldest and most respected medical honor societies in the United States. This prestigious recognition honors physician-scientists under 50 who have made significant contributions to medical research and clinical care. Dr. Ahluwalia's election marks a historic milestone, as he is the first member from both Baptist Health South Florida and Florida International University Herbert Wertheim College of Medicine to be inducted into the ASCI.

Dr. Ahluwalia completed internal medicine training at Cleveland Clinic Health System and fellowship training at Roswell Park Cancer Institute in 2009. He joined Cleveland Clinic, Ohio and soon became the Miller Family Endowed Chair in Neuro-Oncology and the head of operations at Burkhardt Brain Tumor and Neuro-Oncology Center in 2015. He became a full Professor at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University in 2017. Dr. Ahluwalia obtained an MBA from Case Western - Weatherhead School of Management. Soon after, he moved to Miami Cancer Institute (MCI), intending to build the largest cancer program in South Florida. Alongside his leadership responsibilities, Dr. Ahluwalia holds the Fernandez Family Foundation Endowed Chair in Cancer Research at MCI.

Dr. Ahluwalia is driven by a passion for conquering brain tumors, having seen his grandmother succumb to cancer. For over a decade, he has led practice-changing research for developing new therapies for patients with primary brain tumors and brain metastases, resulting in his 250+ peer- reviewed papers. He designed and led the initial studies on combining immunotherapy/targeted therapy and radiosurgery in brain metastases. He co-led the first-in-man trial of Laser Interstitial Thermal Therapy (LITT) for primary brain tumors, which led to US FDA approval. He also designed and led the LASSR trial exploring LITT for brain metastases and radiation necrosis. He also first authored the landmark paper describing the Phase II trial of SurVaxM for glioblastoma in the Journal of Clinical Oncology.Along with a busy practice, he serves as the Principal Investigator (PI) on a $3.9 million NIH R01-funded grant on quantitative imaging phenotypic classifier development for radiomics in glioblastoma. This is the first NIH R01 grant ever received by Baptist Health. He is also the ‘clinical trial leader’ on the $10.4 million PO1 grant focusing on Glioblastoma gender-specific differences (Cosine Consortium). He is the PI on ongoing paradigm-changing FDA-approval-intent studies on blood- brain barrier disruption by Insightec Neuroblate (LIMITLESS, LIBERATE) through Low-Intensity Focused Ultrasound for primary brain tumors and brain metastases. He also chairs the scientific advisory committee of Guardian Research Network (GRN), a nationwide healthcare alliance.

Dr. Ahluwalia has been a leader in organized efforts in neuro-oncology. He currently serves as the chair of the US National Cancer Institute (NCI) South-West Oncology Group (SWOG) Brain Tumor Working Group and the DEI co-chair of SWOG. He also chairs the Scientific Review Committee of the International Gamma Knife Research Foundation. He also serves as a member of the National Brain Tumor Society (NBTS) Roundtable Committee and as founder PI of the coordinating site for the International Radiosurgery Research Foundation.

Dr. Ahluwalia has received several prestigious awards, including the Fellowship of the American Society of Clinical Oncology (ASCO), the National Cancer Institute/CTEP Career Development Award via the American Brain Tumor Consortium (ABTC), ASCO Leadership Development Program, Most Distinguished Physician Award of AAPI, amongst others.

In his free time, Dr. Ahluwalia enjoys spending time with his children, playing and watching tennis, and watching movies with his family.

Esteemed nurse and healthcare leader Vicki Caraway, R.N., BSN, MBA, NE-BC, has been appointed chief nursing officer of Baptist Health Cancer Care, where she will oversee all nursing functions at Miami Cancer Institute and Lynn Cancer Institute.

Ms. Caraway has more than 32 years of oncology nursing experience. Most recently, she was vice president of Nursing Research and Care Management at Florida Cancer Specialists (FCS) and American Oncology Network, sister companies. While there, she established the first FCS-wide genetic counseling program and the first FCS palliative/support care program.

Previously she spent 28 years at Moffitt Cancer Center in Tampa, where she served in many leadership roles, heading strategic organizational-wide initiatives in nursing, revenue cycle, operations and research. She also oversaw the planning, construction and opening of Moffitt’s 207,000-square-foot outpatient satellite facility on the McKinley Campus. Ms. Caraway began her nursing career in Athens, Georgia, where she cared for patients in the surgical and neuro units. She earned her BSN in nursing from the University of Tampa and her MBA from St. Leo University.

At Miami Cancer Institute, Ms. Caraway’s responsibilities will include overseeing all nursing functions, and assuring safety, quality, and high patient and staff satisfaction, as well as nursing excellence.

With an interest in nursing mentorship and palliative and supportive care, Ms. Caraway is a member of the Florida Palliative Care Coalition and winner of the 2018 Diversity Award. She is active in numerous professional committees and enjoys volunteering, spending time with her husband, John, and their family, traveling, antiquing and home renovations.

Scott Lipkin, DPM, has been appointed as Vice President and Chief Research Officer for Baptist Health South Florida. Dr. Lipkin is responsible for the oversight and executive management of the organization’s research enterprise, including financial administration, grant management, protocol development, human subject protections/IRB and compliance.

In addition to his new role, Dr. Lipkin will continue as chief research officer for Miami Cancer Institute, under the leadership of Michael Zinner, M.D., CEO of the Institute. In this role, he is responsible for the executive management of Miami Cancer Institute’s research program, including clinical operations, research administration, biorepository, academic affiliations, Institutional Review Board and compliance.

Dr. Lipkin earned his doctorate of podiatric medicine from the Temple University School of Podiatric Medicine. He then completed his podiatric surgery residency and served as chief resident at St. Mary Hospital in Philadelphia.

He began his career on the medical staff of the Lehigh Valley Health Network (LVHN). He was also chief of the Division of Podiatric Surgery for 10 years. He began participating in clinical research early in his career, serving as the principal or sub-investigator on numerous clinical trials related to diabetic foot wounds and wound healing.

Dr. Lipkin began taking on research positions while maintaining his clinical practice. He chaired LVHN’s institutional review board and led the organization through national accreditation. He then began serving on national panels and councils that focused on research ethics, patient safety and research compliance.

His dedication to the operational and compliance side of the clinical research continuum led him to accept a full-time role in administration in 2010. He served as the chief of the Network Office of Research & Innovation, where he created a centralized research office. In 2014, he transitioned to research consulting.

Dr. Lipkin joined Miami Cancer Institute from Ankura Consulting, where he served as the managing director of the clinical research and compliance practice. In this role, he provided research- and compliance-related advisory services to academic medical centers, cancer centers, children’s hospitals and large health systems throughout the United States.

Dr. Lipkin serves as an adjunct instructor at the Loyola University School of Law, is a member of the Council for Certification of IRB Professionals, and is a frequent presenter at professional events and conferences throughout the country.

Jenny R. Waltzer is chief operating officer of Baptist Health Cancer Care, comprised of both Miami Cancer Institute and The Eugene M. & Christine E. Lynn Cancer Institute. She has more than 18 years of experience in oncology services and healthcare administration.

Prior to joining Baptist Health in August 2024, Ms. Waltzer served as vice president of the Hematology and Oncology, Infusion and Surgical Oncology Service Line at The Mount Sinai Health System in New York. In this role, she demonstrated exceptional leadership in overseeing the surgical services, infusion and other oncology services across the system’s eight hospitals. Her responsibilities included strategic, financial, operational and personnel management, handling the budget for all cancer and infusion programs and driving the financial health of the service line.

In addition to her financial acumen, Ms. Waltzer was instrumental in launching several critical initiatives. She played a key role in the design and implementation of The Tisch Cancer Hospital’s five-year rollout plan, which included a new 24/7 oncology immediate care center. She also successfully launched a Plasmapheresis Collection Center and Monoclonal Antibody Infusion Center during the COVID-19 pandemic, showcasing her ability to respond to urgent healthcare needs with innovative solutions.

Prior to her tenure at Mount Sinai, Ms. Waltzer held significant roles at Northwell Health’s Manhattan Eye, Ear & Throat Hospital, Weill Cornell Medicine, and Memorial Sloan Kettering Cancer Center. In these positions, she consistently demonstrated her capability to enhance operational efficiency, ensure regulatory compliance and improve patient outcomes.

Ms. Waltzer earned a Master of Arts in Psychology from Hunter College and a Bachelor of Arts in Psychology with a Minor in Education from the University of Massachusetts Amherst. Her background in psychology complements her robust healthcare management experience, enabling her to lead with empathy and a deep understanding of patient and staff needs.

Dr. Michael Zinner was the founding chief executive officer, executive medical director and Endowed Chair in Cancer Care at Baptist Health Miami Cancer Institute. A native of Miami, Dr. Zinner returned home to lead the Institute from its inception in 2017, establishing it as a world-class destination for multidisciplinary cancer care, advanced research, and compassionate patient support. Under his leadership, Miami Cancer Institute became a beacon of hope and innovation for patients throughout the region and beyond.

Before returning to South Florida, Dr. Zinner held several of the most prestigious positions in academic surgery. He served as the Moseley Professor of Surgery at Harvard Medical School, the Surgeon-in-Chief at Brigham and Women’s Hospital (BWH), and the Clinical Director of the Dana-Farber/Brigham and Women’s Cancer Center. He also held the Crowley Family Distinguished Chair in the Department of Surgery at Brigham and Women’s Hospital from 1994 to 2016. Earlier in his career, he was Chair of Surgery at the University of California, Los Angeles (UCLA), where he developed one of the nation’s leading programs in surgical oncology.

Dr. Zinner was a pioneer in pancreatic and hepatobiliary surgery and a driving force in elevating standards of care for patients with complex gastrointestinal diseases. Over his distinguished career, he authored more than 265 peer-reviewed publications and served as the past and current Editor of Maingot’s Abdominal Operations, one of the world’s leading surgical textbooks and atlases of gastrointestinal surgery, now in its fourth edition under his editorship.

He was deeply involved in shaping the field of academic surgery through service on numerous national and international boards. Dr. Zinner was a past President of the Association for Academic Surgery, the Society of University Surgeons, and the Society of Surgical Chairs. He served as a Director of the American Board of Surgery, a member of the Board of Directors of the Society for Surgery of the Alimentary Tract, and the Collegium Internationale Chirurgiae Digestivae. He chaired both the Board of Governors and the Board of Regents of the American College of Surgeons and received the Association of Women Surgeons’ National Award for the Advancement of Women in Surgery in 2008.

In 2004, Dr. Zinner co-founded the Center for Surgery and Public Health, a collaboration between Harvard Medical School and the Harvard School of Public Health. The center was dedicated to improving health care quality, safety, and global access to surgical care. His enduring interests included health policy, patient safety, and mentorship, values that shaped his leadership at Miami Cancer Institute and his lifelong commitment to academic medicine.

Dr. Zinner remained an active clinician, educator, and mentor until his passing, known for his surgical precision, humility, and compassion for patients and colleagues alike. At Miami Cancer Institute, he personally recruited more than 60 leading physicians from across the country, many from renowned institutions such as Memorial Sloan Kettering, Dana-Farber, Yale, Mayo Clinic, and the Cleveland Clinic, assembling a team of exceptional talent dedicated to world-class cancer care.

Dr. Zinner passed away on October 25, 2025, at the age of 80. His visionary leadership, humanity, and dedication to excellence continue to inspire the work of Baptist Health and the Miami Cancer Institute. His legacy endures through the thousands of lives he touched, as a surgeon, teacher, leader, and friend.